Rituxan®

Understanding Rituxan® (rituximab)

Rituxan® is a monoclonal antibody used to treat autoimmune diseases and certain types of cancer by targeting CD20, a protein found on B-cells. By binding to CD20, Rituxan® marks B-cells for destruction by the immune system, helping to reduce inflammation and abnormal immune responses in autoimmune diseases while also depleting cancerous B-cells in blood cancers.

How Rituxan® Works:

• Targets and eliminates CD20-positive B-cells, which contribute to autoimmune diseases and blood cancers.
• Reduces inflammation and immune system overactivity in autoimmune conditions.
• Helps slow disease progression and improve symptoms in cancer and immune-mediated disorders.

FDA Approval:

• Rituxan®: Approved in 1997

For more information, please visit the Rituxan® patient website and speak with your healthcare provider to determine if Rituxan® is the right treatment option for you.